ARCUS BIOSCIENCES INC's ticker is RCUS and the CUSIP is 03969F109. A total of 186 filers reported holding ARCUS BIOSCIENCES INC in Q3 2022. The put-call ratio across all filers is 1.07 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,997,817 | -65.9% | 111,299 | -61.4% | 0.00% | -50.0% |
| Q2 2023 | $5,857,587 | +803.0% | 288,409 | +711.0% | 0.00% | – |
| Q1 2023 | $648,651 | +21.3% | 35,562 | +37.5% | 0.00% | – |
| Q4 2022 | $534,867 | -39.6% | 25,864 | -23.5% | 0.00% | – |
| Q3 2022 | $885,000 | +188.3% | 33,831 | +179.5% | 0.00% | – |
| Q2 2022 | $307,000 | -60.9% | 12,106 | -51.3% | 0.00% | – |
| Q1 2022 | $785,000 | +288.6% | 24,861 | +397.2% | 0.00% | – |
| Q4 2021 | $202,000 | -74.3% | 5,000 | -77.8% | 0.00% | – |
| Q3 2021 | $786,000 | +39.9% | 22,515 | +12.6% | 0.00% | – |
| Q1 2021 | $562,000 | +146.5% | 19,997 | +127.2% | 0.00% | – |
| Q4 2020 | $228,000 | -57.5% | 8,803 | -71.9% | 0.00% | – |
| Q3 2020 | $537,000 | -48.3% | 31,310 | -25.4% | 0.00% | – |
| Q2 2020 | $1,038,000 | +221.4% | 41,955 | +40.1% | 0.00% | -100.0% |
| Q4 2018 | $323,000 | – | 29,957 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Invus Financial Advisors, LLC | 1,612,077 | $28,936,782 | 18.14% |
| Octagon Capital Advisors LP | 1,968,000 | $35,325,600 | 5.43% |
| Decheng Capital Management III (Cayman), LLC | 869,790 | $15,612,731 | 5.21% |
| Boxer Capital, LLC | 1,602,200 | $28,759,490 | 1.53% |
| SECTORAL ASSET MANAGEMENT INC | 375,456 | $6,739,435 | 1.31% |
| DAFNA Capital Management LLC | 222,717 | $3,997,770 | 1.24% |
| PFM Health Sciences, LP | 1,405,056 | $25,220,755 | 1.19% |
| Ikarian Capital, LLC | 4,000 | $7,180,000 | 0.86% |
| Capital Impact Advisors, LLC | 24,280 | $435,826 | 0.73% |
| Parkman Healthcare Partners LLC | 205,109 | $3,681,707 | 0.68% |